Drugs Made In America Acquisition Q3 2025 Earnings Report

Drugs Made In America Acquisition EPS Results

• Actual EPS: $0.07
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Drugs Made In America Acquisition Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Drugs Made In America Acquisition Announcement Details

• Quarter: Q3 2025
• Date: 11/18/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Drugs Made In America Acquisition (NASDAQ:DMAA) Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination. The management team brings together professionals with backgrounds in healthcare, life sciences and investment banking, aiming to leverage their combined expertise to target companies that address supply‐chain resilience and onshore production of critical prescription medications. The company is headquartered in New York and serves as a vehicle for investors seeking exposure to the U.S. pharmaceutical manufacturing industry.

Since its initial public offering on the Nasdaq Stock Market, Drugs Made In America Acquisition has been evaluating potential transaction candidates across the United States and is working toward identifying a suitable partner that aligns with its goal of bolstering domestic drug production capabilities. Pending the closing of a qualifying business combination, the SPAC will continue to operate under regulatory guidelines governing blank‐check companies and pursue opportunities intended to create long‐term shareholder value through a combination that reinforces American pharmaceutical independence.